Table 1.
Demographic and clinicopathological characteristics of 100 patients with anal squamous cell carcinoma, by primary treatment modality, April 2012 through May 2023.
| Characteristics |
Total patients (N = 100) |
Surgery group (N = 24) |
CRT group (N = 52) |
CRT-I group (N = 24) |
P |
|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | ||
| Age, years (median, 55) | 0.624 | ||||
| ≤ 55 | 54 (54.0) | 12 (50.0) | 27 (51.9) | 15 (62.5) | |
| > 55 | 46 (46.0) | 12 (50.0) | 25 (48.1) | 9 (37.5) | |
| Gender | 0.760 | ||||
| Male | 20 (20.0) | 6 (25.0) | 10 (19.2) | 4 (16.7) | |
| Female | 80 (80.0) | 18 (75.0) | 42 (80.8) | 20 (83.3) | |
| HPV status | 0.561 | ||||
| Positive | 68 (68.0) | 14 (58.3) | 35 (67.3) | 19 (79.2) | |
| Negative | 15 (15.0) | 4 (16.7) | 9 (17.3) | 2 (8.3) | |
| NT | 17 (17.0) | 6 (25.0) | 8 (15.4) | 3 (12.5) | |
| Tumor differentiation (initial biopsy) | 0.275 | ||||
| High | 11 (11.0) | 3 (12.5) | 8 (15.4) | 1 (4.2) | |
| Moderate | 58 (58.0) | 17 (70.8) | 26 (50.0) | 15 (58.3) | |
| Poor | 31 (31.0) | 4 (16.7) | 18 (34.6) | 9 (37.5) | |
| Clinical T stage | 0.001 | ||||
| cT1 | 15 (15.0) | 8 (33.3) | 5 (9.6) | 2 (8.3) | |
| cT2 | 41 (41.0) | 2 (8.4) | 27 (51.9) | 12 (50.0) | |
| cT3 | 24 (24.0) | 9 (37.5) | 13 (25.0) | 2 (8.4) | |
| cT4 | 20 (20.0) | 5 (20.8) | 7 (13.5) | 8 (33.3) | |
| Clinical N stage | 0.059 | ||||
| cN0 | 25 (25.0) | 10 (41.7) | 12 (23.1) | 3 (12.5) | |
| cN1 | 75 (75.0) | 14 (58.3) | 40 (76.9) | 21 (87.5) | |
| Clinical TNM stage | <0.001 | ||||
| I | 10 (10.0) | 7 (29.2) | 3 (5.8) | 0 (0.0) | |
| II | 46 (46.0) | 3 (12.5) | 29 (55.7) | 14 (58.3) | |
| III | 44 (44.0) | 14 (58.3) | 20 (38.5) | 10 (41.7) | |
| Chemotherapy regimena | <0.001 | ||||
| MMC + 5-FU | 36 (36.0) | 1 (4.2) | 21 (40.3) | 14 (58.3) | |
| Cisplatin + 5-FU | 21 (21.0) | 7 (29.1) | 11 (21.2) | 3 (12.5) | |
| Paclitaxel + cisplatin | 31 (31.0) | 4 (16.7) | 20 (38.5) | 7 (29.2) | |
| None | 12 (12.0) | 12 (50.0) | 0 (0.0) | 0 (0.0) | |
| Total chemotherapy cycles, median (IQR) | 3 (2–4) | 2 (0–4) | 3 (2–4) | 3 (3–4) | — |
a
Includes both concurrent and adjuvant chemotherapy; patients continued with the same regimen throughout the study.
Abbreviations: CRT, chemoradiotherapy; CRT-I, chemoradiotherapy with immunotherapy; NT, not tested; MMC, mitomycin C; 5-FU, 5-fluorouracil; IQR, interquartile range.